C3 mutation-associated atypical hemolytic uremic syndrome with severe renal dysfunction and hypertensive emergency successfully treated with ravulizumab and sacubitril/valsartan: a case report. [PDF]
Yanagidani H +9 more
europepmc +1 more source
Design of miniprotein inhibitors targeting complement C9 to block membrane attack complex assembly. [PDF]
Li M +16 more
europepmc +1 more source
Complement in acute kidney injury: a convergent pathogenic pathway in multifactorial renal damage. [PDF]
Yi D, Yang R, Guo Y, Zhou H, Luan J.
europepmc +1 more source
Thrombotic Events in Patients With Paroxysmal Nocturnal Haemoglobinuria Using Eculizumab: A Post-Marketing Surveillance Sub-Analysis. [PDF]
Ikezoe T +4 more
europepmc +1 more source
Off-label intravitreal eculizumab for geographic atrophy: report of the first two cases. [PDF]
Jorge R +3 more
europepmc +1 more source
Current status and challenges of biologic targeted therapy for myasthenia gravis in China. [PDF]
Gu S, Zhao C.
europepmc +1 more source
Ravulizumab for treatment of paroxysmal nocturnal hemoglobinuria during pregnancy. [PDF]
Höchsmann B +15 more
europepmc +1 more source
A new perspective on AMD pathogenesis: a sequential Factor H-centered view of complement dysregulation. [PDF]
Skerka C +9 more
europepmc +1 more source
Complement role in kidney disease: a comprehensive review and therapeutic innovations. [PDF]
Cortez Ferreira B +7 more
europepmc +1 more source
Attenuating pulmonary injury and inflammation with C5/CD14 inhibition therapy: results from a porcine polytrauma model with blunt chest trauma. [PDF]
Mert Ü +9 more
europepmc +1 more source

